



Express Mail No.: **EV 452 775 546 US**
POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Muller *et al.*

Confirmation No.: 2627

Serial No.: 10/622,618

Art Unit: 1626

Filed: July 17, 2003

Examiner: Anderson, Rebecca L.

For: NOVEL IMMUNOTHERAPEUTIC
AGENTS Attorney Docket No: 9516-200-999
CAM: 501872-999199

REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Celgene Corporation (applicant or assignee) hereby revokes any and all previous powers and appoints:

Practitioners at Customer Number 20583

as his/her/its/their attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

The above mentioned Customer Number.

Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 790-2803

I am the:

- Applicant/Inventor
 Assignee of record of the entire interest. See 37 CFR 3.71.
(*Statement under 37 CFR 3.73(b) is applicable*)

Statement Under 37 C.F.R. 3.73(b)

Celgene Corporation states that it is:

- the assignee of the entire right, title, and interest; or
 an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of either:


- An assignment from the inventors of the patent application identified above to Celgene Corporation in connection with U.S. Application No. 08/909,201, now U.S. Patent No. 5,929,117. The patent application identified above is a continuation of U.S. Application No. 10/243,927, which is a divisional of U.S. Application

No. 09/639,757, now U.S. Patent No. 6,262,101, which is a divisional of U.S. Application No. 08/909,201, now U.S. Patent No. 5,929,117. The assignment was recorded in the United States Patent and Trademark Office on April 12, 1999 at Reel 009899, Frame 0945.

OR

- A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
1. From: To:
The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached.
2. From: To:
The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached.
3. From: To:
The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached.
- Additional documents in the chain of title are listed on a supplemental sheet.
- Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Date: 5/24/05 ASSIGNEE: Celgene Corporation
Signature: 
Typed Name: Sol J. Barer, Ph. D.
Position/TITLE: President and Chief Operating Officer

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

- Total of 1 form is submitted.